Application of fermented lactobacillus mucus MSJK0025 derived from breast milk in prevention and / or treatment of breast cancer

Abstract

The invention relates to an application of breast milk-sourced lactobacillus mucus MSJK0025 in prevention and / or treatment of breast cancer in the technical field of microorganisms. Specifically, the invention relates to an application of a strain of fermented lactobacillus mucus MSJK0025 from breast milk in preparation of a pharmaceutical composition for preventing and / or treating breast cancer, and an application of a strain of fermented lactobacillus mucus MSJK0025 from breast milk in preparation of a probiotic agent for preventing and / or treating breast cancer. The invention provides a new application of the fermented lactobacillus mucus MSJK0025 derived from breast milk in prevention and / or treatment of breast cancer. The fermented lactobacillus mucus MSJK0025 can effectively slow down the early growth of breast tumors. Therefore, the fermented lactobacillus mucus MSJK0025 can be well applied to prevention and / or treatment of breast cancer, especially treatment of early breast cancer, and further is used for improving breast health.

Description

Technical Field

[0001] The present application relates to the field of microbial technology, and in particular to the use of a fermented Lactobacillus mucilaginosus MSJK0025 derived from breast milk in the prevention and / or treatment of breast cancer. Background Art

[0002] Breast cancer is one of the most common malignant tumors in women, usually occurring in the breast glandular epithelial tissue. According to statistics, the incidence rate accounts for 7%-10% of all malignant tumors in the body. Its onset is often related to genetics, and the incidence rate is higher in women between the ages of 40 and 60 and before and after menopause. It is one of the most common malignant tumors that seriously affects women's physical and mental health and even endangers their lives.

[0003] Currently, the main methods for treating breast cancer are surgery and Western medicine. However, surgery is dangerous and not suitable for older or weaker patients. Western medicine often only treats the symptoms but not the root cause, and the effect is not obvious, and it is expensive. Therefore, it is necessary to find new methods for improving or treating breast cancer.

[0004] The fermented mucus lactobacillus MSJK0025 that the application is related to is also separated from healthy parturient breast milk, and research shows that fermented mucus lactobacillus MSJK0025 is relatively outstanding in aspects such as gastric acid resistance, bile salt resistance, intestinal colonization ability, growth rate, and has completed safety evaluation test, commercial batch production. Research data show that fermented mucus lactobacillus MSJK0025 has the advantages of strong tolerance, good safety, low production cost, and has good industrialization prospects. Meanwhile, research data show that fermented mucus lactobacillus MSJK0025 has the effect of preferably improving mastitis and then improving mammary gland health, but it needs further study to the effect and effect of preventing, improving or treating breast cancer. Summary of the invention

[0005] In order to address the deficiencies of the prior art, the present application provides an application of a fermented Lactobacillus mucus MSJK0025 derived from breast milk in the prevention of breast cancer. The fermented Lactobacillus mucus MSJK0025 can effectively slow down the early growth of breast tumors, thereby effectively preventing the occurrence of breast cancer in female mammals including humans, as well as treating and alleviating early breast cancer in female mammals including humans.

[0006] To this end, the first aspect of the present application provides a strain of fermented mucus Lactobacillus ( Limosilactobacillus fermentum ) Use of MSJK0025 in the preparation of a pharmaceutical composition for preventing and / or treating breast cancer.

[0007] The fermented mucus Lactobacillus MSJK0025 used in this application is a strain isolated and screened in the patent application number 202311070808.2, which is deposited in the General Microbiological Center of the China Microbiological Culture Collection Administration Committee with a deposit number of CGMCC No. 26426. The inventors of this application have found through research on this strain that the strain can effectively alleviate the early growth of breast tumors, and can then be effectively used in a pharmaceutical composition for preventing and / or treating breast cancer.

[0008] The pharmaceutical composition in the present application can also include a pharmaceutically acceptable carrier, except comprising fermented mucus lactobacillus MSJK0025. In the present application, the pharmaceutically acceptable carrier includes but is not limited to any pharmaceutically acceptable excipient, surfactant, desiccant, diluent, carrier, adjuvant or additive. Suitable pharmaceutically acceptable carriers can for example be magnesium carbonate, lactose, pectin, dextrin, starch, tragacanth, methylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose and cocoa butter etc. In the present application, pharmaceutically acceptable carriers can be solid, semisolid or liquid.

[0009] In some embodiments, the pharmaceutical composition is administered to female mammals including humans.

[0010] The fermented mucus lactobacillus MSJK0025 in the pharmaceutical composition of the present application can effectively slow down the early growth of breast tumors. Specifically, the tumor volume of female mice with breast cancer in the experimental group administered with fermented mucus lactobacillus MSJK0025 was significantly reduced at the 13th week, and the tumor weight was significantly reduced at the 13th week and the 17th week. Therefore, the pharmaceutical composition of the present application can effectively prevent or treat breast cancer, and can be effectively applied to female mammals including humans.

[0011] The mammals in the present application may be, for example, humans, mice, pigs, cows, sheep, dogs, cats, rabbits, etc.

[0012] In some embodiments, the breast cancer treated by the pharmaceutical composition is early breast cancer.

[0013] In this application, early breast cancer (or early-stage breast cancer) refers to patients with a tumor smaller than 3 cm during surgery, no metastatic lymph nodes are palpable in the axillary area, no distant metastasis, or no metastasis or only micrometastasis in the ipsilateral axillary lymph nodes, and no distant metastasis; including non-invasive cancer.

[0014] The fermented mucus lactobacillus MSJK0025 in the present application can slow down the early growth of breast tumors (the tumor volume of female mice with breast cancer in the experimental group administered with fermented mucus lactobacillus MSJK0025 was significantly reduced at the 13th week, and the tumor weight was significantly reduced at the 13th and 17th weeks), but it has no effect on improving the malignant development of breast tumors. Therefore, the breast cancer treated by the pharmaceutical composition described in the present application is preferably early breast cancer.

[0015] The second aspect of the present application provides the use of a fermented Lactobacillus mucilaginosus MSJK0025 derived from breast milk in the preparation of a probiotic agent for preventing and / or treating breast cancer.

[0016] The fermented mucus lactobacillus MSJK0025 used in this application is a strain isolated and screened in the patent application number 202311070808.2, which is deposited in the General Microbiological Center of the China Microbiological Culture Collection Administration Committee with a deposit number of CGMCC No. 26426. The inventors of this application have found through research on this strain that the strain can effectively alleviate the early growth of breast tumors, and can then be effectively used in probiotics for the prevention and / or treatment of breast cancer.

[0017] The probiotic agent in the present application may include not only fermented mucus Lactobacillus MSJK002, but also other probiotics, etc., which are not limited in the present application.

[0018] In some embodiments, the probiotic agent is administered to female mammals including humans.

[0019] The fermented mucus Lactobacillus MSJK0025 in the probiotic preparation of the present application can effectively slow down the early growth of breast tumors. Specifically, the tumor volume of female mice with breast cancer in the experimental group administered with fermented mucus Lactobacillus MSJK0025 was significantly reduced at the 13th week, and the tumor weight was significantly reduced at the 13th week and the 17th week. Therefore, the probiotic preparation of the present application can effectively prevent or treat breast cancer, and can be effectively applied to female mammals including humans.

[0020] The mammals in the present application may be, for example, humans, mice, pigs, cows, sheep, dogs, cats, rabbits, etc.

[0021] In some embodiments, the breast cancer treated by the probiotic agent is early breast cancer.

[0022] In this application, early breast cancer (or early-stage breast cancer) refers to patients with a tumor smaller than 3 cm during surgery, no metastatic lymph nodes are palpable in the axillary area, no distant metastasis, or no metastasis or only micrometastasis in the ipsilateral axillary lymph nodes, and no distant metastasis; including non-invasive cancer.

[0023] The fermented mucus Lactobacillus MSJK0025 in the present application can slow down the early growth of breast tumors (the tumor volume of female mice with breast cancer in the experimental group administered with fermented mucus Lactobacillus MSJK0025 was significantly reduced at the 13th week, and the tumor weight was significantly reduced at the 13th and 17th weeks), but it has no improvement effect on the malignant development of breast tumors. Therefore, the breast cancer treated with the probiotic agent described in the present application is preferably early breast cancer.

[0024] The third aspect of the present application provides a pharmaceutical composition for preventing and / or treating breast cancer, wherein the pharmaceutical composition contains fermented mucus Lactobacillus MSJK0025.

[0025] The pharmaceutical composition in the present application can also include a pharmaceutically or acceptable carrier, except that the fermented mucus lactobacillus MSJK0025 is included. In the present application, the pharmaceutically acceptable carrier includes but is not limited to any pharmaceutically acceptable excipient, surfactant, desiccant, diluent, carrier, adjuvant or additive. Suitable pharmaceutically acceptable carriers can be, for example, magnesium carbonate, lactose, pectin, dextrin, starch, tragacanth, methylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose and cocoa butter etc. In the present application, pharmaceutically acceptable carriers can be solid, semisolid or liquid.

[0026] The fourth aspect of the present application provides a probiotic agent for preventing and / or treating breast cancer, wherein the probiotic agent contains fermented mucus Lactobacillus MSJK0025.

[0027] The probiotic agent in the present application may include not only fermented mucus Lactobacillus MSJK0025 live bacteria, but also other probiotics, etc., which are not limited in the present application.

[0028] The beneficial technical effect of the present application is: the present application provides a new application of a fermented mucus lactobacillus MSJK0025 derived from breast milk in the prevention and / or treatment of breast cancer. The tumor volume of female mice with breast cancer in the test group administered with fermented mucus lactobacillus MSJK0025 was significantly reduced at week 13, and the tumor weight was significantly reduced at weeks 13 and 17. Therefore, fermented mucus lactobacillus MSJK0025 can be well used in the prevention and / or treatment of breast cancer, especially in the treatment of early breast cancer, and then used to improve breast health. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 This is a comparison chart of the tumor volumes of mice in the model control group and the fermented mucus Lactobacillus group in Example 1.

[0030] Figure 2 This is a comparison chart of the tumor weights of mice in the model control group and the fermented Lactobacillus mucus group in Example 1.

[0031] Figure 3 These are the appearances of the whole-body tumors of mice in the model control group and the fermented Lactobacillus mucus group in Example 1; wherein A represents the model control group and B represents the fermented Lactobacillus mucus group. Biological Deposit

[0032] Lactobacillus mucilaginosus fermentation Limosilactobacillus fermentum )MSJK0025, the deposit number is CGMCCNo.26426, the depository is the General Microbiology Center of China Culture Collection Administration (abbreviated as: CGMCC, address: No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing), and the deposit time is January 9, 2023. DETAILED DESCRIPTION

[0033] In order to make the present application easier to understand, the present application will be further described in detail below in conjunction with the examples, which are merely illustrative and are not intended to limit the scope of application of the present application. The raw materials or components used in the present application can be obtained through commercial routes or conventional methods unless otherwise specified.

[0034] The experimental animals in the following examples are MMTV-PyMT transgenic mice, female, 6 weeks old. The experimental animals were provided by Jiangsu Huachuang Xinnuo Pharmaceutical Technology Co., Ltd., certificate: SCXK (Su) 2020-0009.

[0035] Example 1: Evaluation of the efficacy of fermented Lactobacillus mucilaginosus MSJK0025 in preventing and treating breast cancer 1. Animal grouping and drug administration MMTV-PyMT transgenic mice (female, 6 weeks old) were selected and after adaptive feeding, the mice were randomly divided into two groups, namely, a model control group and a fermented Lactobacillus mucus group, with 32 mice in each group, for a total of 64 mice.

[0036] From 6 weeks of age, the model control group and the fermented mucus lactobacillus group were administered with drugs, the fermented mucus lactobacillus group was administered 3 times / week, and each mouse was given 0.5 mL of sample by oral gavage, and the model control group was administered 3 times / week, and each mouse was given 0.5 mL of water by oral gavage. The sample administered to the fermented mucus lactobacillus group was prepared as follows: 20 mg of fermented mucus lactobacillus MSJK0025 dry powder was weighed, 20 ml of water was added, and the powder solution was prepared as a sample for later use.

[0037] 2. Efficacy testing When the animals reached 13 weeks, 15 weeks, 17 weeks, and 19 weeks of age, 8 mice were selected from each group for the following tests: (1) Weigh your body weight; (2) Use a standard caliper to measure the tumor volume at the mammary gland (if not measured, it is recorded as 0). Because mice have multiple diffuse tumors in different parts of the ventral side, only the largest tumor near the mammary gland is selected for measurement and record; (3) After killing the mice, the whole-body tumors were removed, weighed, and recorded, and photographed; (4) Collect blood and separate serum: Detect serum CA153, VEGF, and CEA levels using ELISA kits.

[0038] 3. Experimental results (1) Expression levels of CA153, VEGF, and CEA in mouse serum The expression levels of CA153, VEGF and CEA in mouse serum were detected using mouse carcinoembryonic antigen (CEA; CD66) ELISA research kit (MM-0633M1, Jiangsu Enzyme Absorption Industry Co., Ltd., China), mouse vascular endothelial growth factor (VEGF) ELISA research kit (MM-0128M1, Jiangsu Enzyme Absorption Industry Co., Ltd., China) and mouse carbohydrate antigen 15-3 (CA15-3) ELISA research kit (MM-47737M1, Jiangsu Enzyme Absorption Industry Co., Ltd., China), respectively. The results are shown in Table 1.

[0039] Table 1: Expression levels of CA153, VEGF and CEA in mouse serum (n=8)

[0040] Note: Compared with the model control group, * p <0.05,** p <0.01 As shown in Table 1, compared with the model control group, the expression of VEGF and CEA in the serum of mice in the fermented mucus lactobacillus group was slightly reduced at the 13th week, among which the expression of CEA was more significantly reduced, but it was significantly increased at 19th week, and there was no significant difference at other times.

[0041] (2) Mouse tumor volume The tumor volumes of mice in the model control group and fermented Lactobacillus mucus group are shown in Table 2 and Figure 1 shown.

[0042] Table 2: Mouse tumor volume detection results (n = 8)

[0043] Note: Compared with the model control group, * p <0.05,** p <0.01 From Table 2 and Figure 1 It can be seen that compared with the model control group, the tumor volume of mice in the fermented mucinous lactobacillus group was significantly reduced at the 13th week, and there was no significant difference at other times. This shows that the administration of fermented mucinous lactobacillus MSJK0025 can slow down the growth of early breast tumors.

[0044] (3) Mouse tumor weight The tumor weights of mice in the model control group and fermented Lactobacillus mucus group are shown in Table 3 and Figure 2 As shown, and the whole body tumor pictures of mice are as follows Figure 3 shown.

[0045] Table 3: Mouse tumor weight test results (n = 8)

[0046] Note: Compared with the model control group, * p <0.05 From Table 3 and Figure 2 It can be seen that compared with the model control group, the tumor weight of mice in the fermented mucus lactobacillus group was significantly reduced at the 13th and 17th weeks, and there was no significant difference at other times. Figure 3 It can be seen that compared with the model control group, the tumor weight of mice in the fermented mucin Lactobacillus group was significantly reduced at the 13th and 17th weeks, and there was no significant difference at other times. This shows that the administration of fermented mucin Lactobacillus MSJK0025 can slow down the growth of early breast tumors.

[0047] The above results show that fermented mucus lactobacillus MSJK0025 has the effect of slowing down the early growth of breast tumors, but has no effect on the malignant development of breast tumors. Therefore, fermented mucus lactobacillus MSJK0025 can be used in the prevention and treatment of breast cancer (especially the treatment of early breast cancer).

[0048] It should be noted that the embodiments described above are only used to explain the present application and do not constitute any limitation to the present application. The present application is described with reference to typical embodiments, but it should be understood that the words used therein are descriptive and explanatory words, rather than restrictive words. The present application may be modified as specified within the scope of the claims of the present application, and the present invention may be revised without departing from the scope and spirit of the present application. Although the present application described therein relates to specific methods, materials and embodiments, it does not mean that the present application is limited to the specific examples disclosed therein. On the contrary, the present application can be extended to all other methods and applications with the same functions.

Claims

1. Fermented Lactobacillus mucilaginosus from breast milk ( Limosilactobacillus fermentum ) Use of MSJK0025 in the preparation of a pharmaceutical composition for preventing and / or treating breast cancer.

2. The use according to claim 1, characterized in that: The administration object of the pharmaceutical composition is female mammals including humans.

3. The use according to claim 1 or 2, characterized in that: The breast cancer treated by the pharmaceutical composition is early breast cancer.

4. Application of fermented Lactobacillus mucilaginosus MSJK0025 derived from breast milk in the preparation of a probiotic agent for preventing and / or treating breast cancer.

5. The use according to claim 4, characterized in that: The subjects for taking the probiotics are female mammals including humans.

6. The use according to claim 4 or 5, characterized in that: The breast cancer treated by the probiotic agent is early breast cancer.

7. A pharmaceutical composition for preventing and / or treating breast cancer, characterized in that: The pharmaceutical composition contains fermented mucus lactobacillus MSJK0025.

8. A probiotic agent for preventing and / or treating breast cancer, characterized in that: The probiotic agent contains fermented mucus lactobacillus MSJK0025.

Images